ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Railways
  • World
    • Economy
    • Politics
    • Markets
  • Survey
  • videos
  • photos
  • ZNAA'22
  • Trending News
    • Viral News
    • Travel
    • People
    • Entertainment
    • Sports
  • More ...
    • VIDEOS
    • PHOTOS
BREAKING NEWS
  • Whopping 1 lakh jobs on the cards in aviation and aeronautical manufacturing sector by 2024, says Minister
  • Money Guru: 10 funds for financial independence, this 15th August - details
  • India's forex reserves jump 60x since 1990s, surge 335 times since Independence | Check this data
  • India@100: Anil Singhvi predicts Nifty will reach 1,75,000 in next 25 years - Here's why
Read in App
Business News » Markets News

Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100

Aurobindo Pharma Q3 FY21 revenue, operating profits and PAT were a tad below the estimates. Sales at Rs 6365 cr is up 8% yoy (slightly below estimates), attributable to an 11.3% yoy growth in the formulations segment, while API sales were down 13.6% yoy. OPM expanded by 100 BPS yoy to 21.5% (estimated OPM 22%) led by a 310 bps expansion in gross margins, which were partly offset by an increase in other expenses.

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100
Aurobindo Pharma operating profits for the quarter at Rs 1368 cr is up by 13.3% yoy. Adjusting for one-off gains, PAT stood at Rs 836 cr, up 18.5% yoy but missed estimates: Reuters

Aurobindo Pharma Q3 FY21 revenue, operating profits and PAT were a tad below the estimates. Sales at Rs 6365 cr is up 8% yoy (slightly below estimates), attributable to an 11.3% yoy growth in the formulations segment, while API sales were down 13.6% yoy. OPM expanded by 100 BPS yoy to 21.5% (estimated OPM 22%) led by a 310 bps expansion in gross margins, which were partly offset by an increase in other expenses. Sharekhan retains their Buy recommendation on Aurobindo Pharma with a revised Price target of Rs 1100.

Aurobindo Pharma operating profits for the quarter at Rs 1368 cr is up by 13.3% yoy. Adjusting for one-off gains, PAT stood at Rs 836 cr, up 18.5% yoy but missed estimates. Aurobindo’s injectables business is fast gaining traction with increasing number of regulatory approvals and geographic expansion.

See Zee Business Live TV Streaming Below:

Aurobindo Pharma is also in the midst of commissioning an injectables facility in the US and is also setting up a dedicated facility at Vizag for Europe and RoW markets. Based on this, the annual run-rate of the injectables business is expected to reach $ 650-700 million over the next three years versus $ 380 million now. The US formulations business is also on a strong growth footing, backed by a sturdy product pipeline (50 products to be launched in the US each in FY21 and FY22) and growth in base business.

Aurobindo Pharma’s European business also revived, staging a double-digit revenue growth. Driven by the transition in favor of TLD, the anti-retro-viral (ARV) segment’s revenues are expected to grow strongly. Further, Aurobindo is investing Rs 1500 cr ($200-220 million) annually towards capacity expansion over FY21 and FY22, which offers ample growth visibility. In the long term, vaccines and APIs are expected to be the growth drivers.

Aurobindo Pharma is looking to double its API sales over the next 4 years, largely driven by the capex under the PLI scheme, though it is at planning stage. It would be developing PCV (Pneumococcal Conjugate Vaccine) and has also entered into agreement with a US company to manufacture viral vaccines. Also it is doubling its vaccine capacity to 440 million doses from 220 million doses by June 2021. Successful clearance from USFDA for five plants is awaited as the company has submitted its responses. In the long term, focus on building and developing a strong portfolio of specialty products (biosimilars, oncology, inhalers, transdermal patches, etc) would be key growth drivers.

Aurobindo Pharma Key positives:

European sales grew 13.2% yoy, better than estimates
ARV business grew sturdily by 41.5% yoy due to transition to combination drug TLD
OPM expanded by 100 bps y-o-y to 21.5% backed by a 310 bps expansion in gross margins
Aurobindo Pharma turned cash positive with net cash of Rs 117 cr as of December 2020

Aurobindo Pharma Key negatives:

API segment revenues declined by 13.6% yoy due to a 24.3% decline in Betalactum sales
USFDA clearance for five plants (unit I, IX, XI, VII and US) is yet to be received

Aurobindo Pharma Key Risks:

Delay in resolution of USFDA issues and product approvals; change in regulatory landscape; and negative outcome of key facility inspection by USFDA can affect earnings prospects.

 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Aurobindo PharmaAurobindo
Reported By: ZeeBiz WebTeam
Written By: Rahul Kamdar
Edited By: Harish Dugh
Updated: Fri, Feb 12, 2021
12:08 pm
Mumbai, ZeeBiz WebDesk
RELATED NEWS
SEBI issues warning letter to Aurobindo Pharma over US FDA audit SEBI issues warning letter to Aurobindo Pharma over US FDA audit
Aurobindo Pharma, JSPL, Medplus Health, Delhivery, and Campus shares surge after Q4 results – know what brokerages/analyst say Aurobindo Pharma, JSPL, Medplus Health, Delhivery, and Campus shares surge after Q4 results – know what brokerages/analyst say
DGGI acts on pharma companies for GST evasion; Dr Reddy's, Glenmark, Aurobindo Pharma, Mylan and Cipla come under hammer DGGI acts on pharma companies for GST evasion; Dr Reddy's, Glenmark, Aurobindo Pharma, Mylan and Cipla come under hammer
Aurobindo Pharma shares jump 6.5% after company terminates pact with Cronus Pharma to buy controlling stake Aurobindo Pharma shares jump 6.5% after company terminates pact with Cronus Pharma to buy controlling stake
Aurobindo Pharma shares fall almost 9% amid weak US business and below estimate Q1 numbers Aurobindo Pharma shares fall almost 9% amid weak US business and below estimate Q1 numbers

LATEST NEWS

Har Ghar Tiranga campaign: India Post delivering National Flag for FREE; Steps to buy Tricolour online at ePostoffice portal

International travellers ALERT! Airlines asked to share passengers' information flying abroad - Check latest rule

Samsung Galaxy Unpacked Event today - What to expect, Live streaming details, when and where to watch Samsung event

Shifting gears! Majority of EV owners say charging is no hassle, finds survey

Why didn't BJP try to stop Nitish Kumar from leaving NDA?

What Infosys CEO Salil Parekh said on IT spends

Countering China: Joe Biden signs $280 billion bill to boost chip production

AP CFW MLHP Recruitment 2022: Jobs alert! Vacancies notified at cfw.ap.nic.in - How to apply online; know salary

Stock Markets: REVEALED! Why world economies fearing recession but India is emerging even stronger

7th Pay Commission to stay! Govt not mulling 8th Pay commission; Is performance-based increment for central government employees on the cards?

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2022. India Dot Com Private Limited. All Rights Reserved.
LIVE TV